China Resources Pharmaceutical Group (640) Stock Overview
An investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
640 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
China Resources Pharmaceutical Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.52 |
| 52 Week High | HK$0.71 |
| 52 Week Low | HK$0.47 |
| Beta | -0.40 |
| 1 Month Change | -5.50% |
| 3 Month Change | 4.25% |
| 1 Year Change | -10.43% |
| 3 Year Change | -36.42% |
| 5 Year Change | -1.90% |
| Change since IPO | -48.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| 640 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 2.0% | -1.5% | -3.0% |
| 1Y | -10.4% | 20.8% | -0.7% |
Return vs Industry: 640 underperformed the German Pharmaceuticals industry which returned 21.1% over the past year.
Return vs Market: 640 underperformed the German Market which returned -1.4% over the past year.
Price Volatility
| 640 volatility | |
|---|---|
| 640 Average Weekly Movement | 7.3% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in DE Market | 13.2% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: 640 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 640's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 85,600 | n/a | www.crpharm.com |
China Resources Pharmaceutical Group Limited, an investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. It operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. The company offers a range of chemical drugs, Chinese medicines, and biological drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular, metabolism, intravenous infusion, and cerebrovascular diseases, alimentary tract, endocrine diseases, respiratory diseases, orthopedics, nephrology, rheumatology and immunology, medical nutrition, pediatrics, genitourinary system, dermatological diseases, blood products, therapeutic infusions, antitumor drugs, medicine for cough and cold, anti-infection drugs, and psychoneurosis.
China Resources Pharmaceutical Group Limited Fundamentals Summary
| 640 fundamental statistics | |
|---|---|
| Market cap | €3.32b |
| Earnings (TTM) | €515.20m |
| Revenue (TTM) | €34.36b |
Is 640 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 640 income statement (TTM) | |
|---|---|
| Revenue | CN¥269.57b |
| Cost of Revenue | CN¥225.07b |
| Gross Profit | CN¥44.51b |
| Other Expenses | CN¥40.47b |
| Earnings | CN¥4.04b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.64 |
| Gross Margin | 16.51% |
| Net Profit Margin | 1.50% |
| Debt/Equity Ratio | 60.9% |
How did 640 perform over the long term?
See historical performance and comparisonDividends
Does 640 pay a reliable dividends?
See 640 dividend history and benchmarks| China Resources Pharmaceutical Group dividend dates | |
|---|---|
| Ex Dividend Date | Jun 17 2026 |
| Dividend Pay Date | Aug 03 2026 |
| Days until Ex dividend | 5 days |
| Days until Dividend pay date | 52 days |
Does 640 pay a reliable dividends?
See 640 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/11 06:31 |
| End of Day Share Price | 2026/06/11 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
China Resources Pharmaceutical Group Limited is covered by 18 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bo Li | BofA Global Research |
| Yanyin Zhu | China International Capital Corporation Limited |
| Zhuhong Chen | China Merchants Securities (HK) Co., Ltd |